Moderna, Inc. MRNA
Healthcare · Biotechnology · United States · S&P 500
Based on the available data, Moderna, Inc. gets an algorithmic score of 56/100. It trades at 203.46 $, with a bullish technical trend (RSI 76.4) and 192.5% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low-debt balance sheet.
Weaknesses
- Low ROE (-39.0%).
- Thin net margin (-141.4%): vulnerable to costs.
- Shrinking revenue (-53.3% per year).
- Negative free cash flow.
- High beta (1.50): amplifies index moves.
Fundamentals
| Forward P/E | -45.53 |
| P/B | 12.01 |
| EV/EBITDA | -35.25 |
| P/S | 36.46 |
| ROE % | -39.00 |
| ROA % | -13.26 |
| Gross margin % | -66.02 |
| Operating margin % | -557.93 |
| Net margin % | -141.43 |
| Revenue growth % (y/y) | 2.10 |
| Revenue CAGR % | -53.30 |
| Debt/Equity % | 19.04 |
| Current ratio | 2.29 |
| FCF yield % | -2.55 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | +47.5 % |
| 3 months | +190.5 % |
| 6 months | +321.9 % |
| YTD | +559.3 % |
| 1 year | +730.8 % |
| 3 years | +103.5 % |
| 5 years | -53.1 % |
Risk
| 1-year volatility | 192.5 % |
| Beta | 1.50 |
| 5-year max drawdown | -95.1 % |
| Sharpe 1A | 1.62 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.